TScan Therapeutics, Inc.

NasdaqGM:TCRX Stock Report

Market Cap: US$371.1m

TScan Therapeutics Dividend

Dividend criteria checks 0/6

TScan Therapeutics does not have a record of paying a dividend.

Key information

n/a

Dividend yield

n/a

Payout ratio

Industry average yield2.9%
Next dividend pay daten/a
Ex dividend daten/a
Dividend per sharen/a
Earnings per share-US$1.86
Dividend yield forecast in 3Yn/a

Recent dividend updates

No updates

Recent updates

Subdued Growth No Barrier To TScan Therapeutics, Inc.'s (NASDAQ:TCRX) Price

Mar 23
Subdued Growth No Barrier To TScan Therapeutics, Inc.'s (NASDAQ:TCRX) Price

Is TScan Therapeutics (NASDAQ:TCRX) Using Too Much Debt?

Feb 17
Is TScan Therapeutics (NASDAQ:TCRX) Using Too Much Debt?

TScan Therapeutics, Inc. (NASDAQ:TCRX) Just Reported, And Analysts Assigned A US$10.75 Price Target

Mar 11
TScan Therapeutics, Inc. (NASDAQ:TCRX) Just Reported, And Analysts Assigned A US$10.75 Price Target

TScan Therapeutics GAAP EPS of -$0.63 beats by $0.13, revenue of $4.05M beats by $1.05M

Aug 10

TScan Therapeutics appoints Debora Barton as Chief Medical Officer

Jul 07

Here's Why We're Watching TScan Therapeutics' (NASDAQ:TCRX) Cash Burn Situation

May 22
Here's Why We're Watching TScan Therapeutics' (NASDAQ:TCRX) Cash Burn Situation

Will TScan Therapeutics (NASDAQ:TCRX) Spend Its Cash Wisely?

Jan 17
Will TScan Therapeutics (NASDAQ:TCRX) Spend Its Cash Wisely?

We're Keeping An Eye On TScan Therapeutics' (NASDAQ:TCRX) Cash Burn Rate

Oct 18
We're Keeping An Eye On TScan Therapeutics' (NASDAQ:TCRX) Cash Burn Rate

Stability and Growth of Payments

Fetching dividends data

Stable Dividend: Insufficient data to determine if TCRX's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if TCRX's dividend payments have been increasing.


Dividend Yield vs Market

TScan Therapeutics Dividend Yield vs Market
How does TCRX dividend yield compare to the market?
SegmentDividend Yield
Company (TCRX)n/a
Market Bottom 25% (US)1.6%
Market Top 25% (US)4.8%
Industry Average (Biotechs)2.9%
Analyst forecast in 3 Years (TCRX)n/a

Notable Dividend: Unable to evaluate TCRX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate TCRX's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate TCRX's payout ratio to determine if its dividend payments are covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as TCRX has not reported any payouts.


Discover strong dividend paying companies

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.